O músculo estriado esquelético é uma entidade extremamente versátil, capaz de alterar seus padrões e características fenotípicas sob diversas condições, tais como, atividade neuromuscular, estimulação elétrica, idade, atividade hormonal e exercício físico. Sabe-se também que o balanço entre estímulos atróficos e hipertróficos controlam diretamente a massa muscular do indivíduo e estas variações implicam diretamente não apenas sobre o volume muscular, mas também conteúdo de proteínas e produção de força. Neste sentido, a atrofia muscular (perda de massa muscular) é caracterizada tanto pela diminuição na área de secção transversa das fibras musculares, como também pelo decréscimo no conteúdo de proteínas miofibrilares e consequente redução do volume muscular. Esta atrofia muscular pode ocorrer sob diversas condições clinicas e/ou patológicas, acarretando na diminuição ou perda da massa magra levando à uma consequente diminuição da atividade física, da qualidade de vida e inclusive pior resposta ao tratamento, ocasionando consequentemente aumento da mortalidade. Fica claro desta maneira, que, os métodos que visam a prevenção ou tratamento à atrofia muscular tem importante relevância clínica em muitos grupos de pacientes, além de ser um importante fator contribuinte na qualidade de vida e autonomia destes indivíduos. Com isso o estudo de determinados tratamentos que combatam a atrofia muscular torna-se de vital importância, dentre os quais, vem ganhando destaque o &#x3B2;Hidroxi &#x3B2;Metilbutirato (HMB). Deste modo teve-se como objetivo neste trabalho verificar a efetividade do HMB em prevenir a atrofia muscular induzida por dexametasona (DEXA). Para isto, foram utilizados 32 animais da linhagem Wistar com idade de 60 dias, distribuídos nos seguintes grupos: Grupo Experimental Placebo (GEP), n=8, tratados por 10 dias consecutivos com gavagem e injeção intraperitoneal, ambas contendo apenas solução salina; Grupo Experimental Dexametasona (GED), n=8, tratados por 10 dias consecutivos com gavagem contendo solução salina e injeção intraperitoneal contendo dexametasona; Grupo Experimental HMB (GEH), n=8, tratados por 10 dias consecutivos com gavagem contendo HMB e injeção intraperitoneal contendo solução salina; e Grupo Experimental Dexametasona + HMB (GEDH), n=8, tratados por 10 dias consecutivos com gavagem contendo HMB e injeção intraperitoneal contendo DEXA. Os animais foram acondicionados em caixas coletivas com 4 animais por caixa, com comida e agua à vontade em sala climatizada com temperatura de 22o e respeitando o ciclo de 12 horas claro/escuro. Finalizados os dez dias de tratamento, os animais foram eutanasiados para a coleta do material. Após as análises, as médias dos grupos para peso corpóreo dos animais, peso muscular e os valores da morfometria foram todos submetidos ao teste One-Way ANOVA, seguidos do Teste de Tukey, sendo o valor considerado estatisticamente significante de p<0,05. Ao final pôde-se concluir que, no delineamento experimental aqui aplicado, o HMB não foi capaz de atenuar ou prevenir a perda de peso corporal induzida pela DEXA, sendo que o efeito anticatabólico esperado pelo HMB não repercutiu no musculo EDL, contudo foi capaz de prevenir a atrofia no musculo sóleo. / The skeletal muscle is an extremely versatile entity, able to change their patterns and phenotypic characteristics under various conditions such as neuromuscular activity, electrical stimulation, age, hormonal activity and exercise. It is also known that the balance between atrophic and hypertrophic stimuli directly control the muscle mass of the individual and these changes directly affect not only on muscle volume, but also protein content and production strength. In this sense, muscle atrophy (loss of muscle mass) characterized by both, the decrease in cross-sectional area of muscle fibers, but also by decreasing the content of myofibrillar proteins and consequent reduction in muscle volume. This muscle atrophy may occur in various pathological conditions, resulting in decrease or loss of lean body mass leading to a consequent reduction in physical function, quality of life and even worse response to treatment, thus leading to increased mortality. It is clear in that way that the methods aimed at preventing or treating muscle atrophy has important clinical relevance in many groups of patients, as well as being a major contributing factor in the quality of life and autonomy of individuals. Thus, the study of certain treatments that combat muscle atrophy become of vital importance, among which highlight is winning the &#x3B2;-hydroxy-&#x3B2;-methylbutyrate (HMB). Thus, it is aimed in this study to assess the effectiveness of HMB to prevent muscle atrophy induced by dexamethasone (DEXA). For this, we used 32 Wistar animals aged 60 days, distributed in the following groups: experimental group Placebo (GEP), n = 8, treated for 10 consecutive days with gavage and intraperitoneal injection, both containing only saline. Experimental group Dexamethasone (GED), n = 8, treated for 10 consecutive days with gavage containing saline and intraperitoneal injection containing dexamethasone. Experimental group HMB (GEH), n = 8, treated for 10 consecutive days with gavage containing HMB and intraperitoneal injection containing saline solution and Experimental Group Dexamethasone + HMB (GEDH), n = 8, treated for 10 consecutive days with gavage containing HMB and intraperitoneal injection containing DEXA. The animals were placed in collective boxes with 4 animals per cage with food and water at will in a room with 22o temperature and respecting the light / dark 12-hour cycle. Completed the ten days of treatment, the animals were euthanized to collect the material. After the analysis, the mean body weight to groups of animals, muscle weight and values of morphometry were all subjected to one-way ANOVA followed by Tukey test, with the amount considered statistically significant at p <0.05. At the end, it could be concluded that the experimental design applied here, the HMB was not able to mitigate or prevent the loss of body weight induced by DEXA, and the anti-catabolic effect expected by HMB not reflected in the EDL muscle, but was able to prevent atrophy in the soleus muscle.

As proteínas de choque térmico exercem um papel regulatório chave na defesa celular. Com o intuito de investigar o papel da proteína de choque térmico 70 kDa induzível (HSP70) na atrofia muscular e subsequente recuperação, os músculos extensor longo dos dedos e sóleo de camundongos transgênicos hiperexpressantes de HSP70 foram imobilizados durante 7 dias e subsequentemente liberados da imobilização e avaliados após 7 dias. Houve redução da área de secção transversal (AST) das fibras musculares após imobilização nos animais selvagens e HSP70 porém, apenas os animais HSP70 recuperaram a AST. O número de células satélites bem com a contração tetânica máxima permaneceram inalterados somente nos animais HSP70. O aumento da expressão dos genes atrogin-1 e MuRF-1 induzido pela imobilização foi atenuado nos animais HSP70. Nosso trabalho sugere que a HSP70 é importante para a melhor recuperação estrutural e funcional do músculo após imobilização, e este resultado pode estar relacionado à preservação da quantidade de células satélites e regulação de atrogenes. / Heat shock proteins play a key regulatory role in cellular defense. In order to investigate the role of the inducible 70-kDa heat shock protein (HSP70) in skeletal muscle atrophy and subsequent recovery, extensor digitorum longus and soleus muscles from overexpressing HSP70 transgenic mice were immobilized during 7 days and subsequently released from immobilization and evaluated after 7 days. There was a decrease in myofiber cross-sectional area after immobilization in both wild type and HSP70 mice, but only myofibers from HSP70 mice recovered their size. The number of satellite cells and the muscle tetanic contraction were unchanged only in the muscles from HSP70 mice. In addition, the increase of atrogin-1 and MuRF-1 gene expression was attenuated in HSP70 mice. Therefore, our study suggests that the HSP70 is important for structural and functional recovery of muscles after immobilization and this effect might be associated with preservation of satellite cell amount and regulation of atrogenes.

Skeletal muscle atrophy is a debilitating condition caused by pathological conditions including cancer cachexia, disuse and denervation. Disuse atrophy is characterized by reduction in fiber size, fiber-type change and induction of markers of atrophy such as MuRF1 and Fn14. Recent studies have focused on understanding the fundamental role of signalling pathways and the proteolytic system in response to muscle atrophy. Unfortunately the exact mechanisms behind atrophy remain poorly understood. I recently demonstrated that cIAP1 and/or cIAP2 proteins are critical regulators of NF-kB activation, which has been shown to be involved in skeletal muscle atrophy. Here, I used genetic and pharmacological means to investigate the role of cIAP1 in a denervation-induced skeletal muscle atrophy model. Interestingly, I found that upon denervation loss of cIAP1 rescues muscle fiber size, prevents fiber-type changing and inhibits the expression of MuRF1 and Fn14. Moreover, treatment of mice with Smac mimetic compounds (SMC), a novel class of small molecule IAP antagonists, showed successful knockdown of cIAP1 in muscle and protects against denervation-induced muscle atrophy. Taken together, these data reveal that cIAP1 is both a novel mediator of skeletal muscle atrophy and an important therapeutic target.

HDAC6 est une histone déacétylase hautement conservée, principalement cytoplasmique. Contrairement à d'autres désacétylases, HDAC6 a une spécificité de substrat unique pour les protéines non - histones . Outre les domaines de désacétylation, HDAC6 contient également un domaine de liaison à l'ubiquitine , qui relie HDAC6 de la voie ubiquitine / protéasome .L’atrophie du muscle squelettique est une condition sévère de perte progressive de masse musculaire au cours de certaines maladies telles le cancer, le diabète, le SIDA ou également immobilizations prolongées. Le contrôle de la masse musculaire est sous la dépendance d’un équilibre entre les processus anaboliques et cataboliques. L’atrophie se caractérise par une augmentation substantielle de la dégradation des protéines par le système ubiquitine-protéasome, causée par l'expression d'une série de gènes spécifiques, les atrogenes . Un des atrogenes induits plus spectaculaire est le muscle spécifique de l'ubiquitine ligase E3 MAFbx/Atrogin-1, qui prend soin de la dégradation de MyoD et de eIF3 -f. La dégradation de ces deux protéines inhibe l'expression de gènes et la traduction myotrophiques empêchant le remplacement de protéines dégradées.Récemment, nous avons identifié l’Histone Deacetylase 6 (HDAC6) comme un nouvel atrogène. L’expression de HDAC6 augmente au cours de l’atrophie musculaire, à la fois chez la souris et l’homme, à travers un mécanisme FOXO3 -dépendante. La déplétion de cet enzyme in vivo (electroporation de l’shRNA contre HDAC6 dans des muscle squelettiques de souris ou analyse de souris invalidées pour ce gène) protège contre l’atrophie. De plus, l’inhibition de HDAC6 après déclenchement de l’atrophie peut aussi atténuer le phénotype. Lors de la caractérisation du mécanisme d’action de HDAC6, nous avons montré que HDAC6 intéragit avec MAFbx et que elle est nécessaire pour l’ubiquitination de MyoD par MAFbx. Nos résultats montrent que la surexpression d’un mutant MyoD resistant à la degradation par MAFbx protège contre l’atrophie provoqué par la denervation.. De plus, certaines données préliminaires indiquent une implication de HDAC6 dans la dégradation de eIF3-f et dans le processus de autophagy dans le tissu musculaire , révélant une double rôle de HDAC6 dans le muscle squelettique .Ces preuves suggèrent que HDAC6 représente potentiellement une cible utile pour des traitements curatifs. / HDAC6 is a highly conserved histone deacetylase, mostly cytoplasmic. Unlike other deacetylases, HDAC6 has unique substrate specificity for non-histone proteins. Besides the deacetylation domains, HDAC6 also contains an ubiquitin-binding domain, which links HDAC6 to the ubiquitin/proteasome pathway. Skeletal muscle atrophy is a severe condition of muscle mass loss occurring during aging or in many clinical disorders as cancer, diabetes and AIDS. The maintenance of muscle mass is subtly controlled by an equilibrium between catabolic and anabolic processes. Muscle atrophy results as a partial suppression of protein synthesis and a substantial increase of protein breakdown by the ubiquitin-proteasome system, caused by the expression of a series of specific genes, the atrogenes. One of the atrogenes induced more dramatically is the muscle specific E3 ubiquitin ligase MAFbx/Atrogin-1, which takes care of the degradation of MyoD and of eIF3-f. Degradation of those two proteins inhibits expression of myotrophic genes and translation preventing the replacement of degraded proteins.We identified HDAC6 as a new atrogene. HDAC6 expression is up regulated during muscle atrophy in mouse and human through a mechanism FoxO3-dependent. In vivo depletion of this enzyme by shRNA electroporation or homologous recombination gives protection against atrophy and its inhibition during atrophy can partially reverse the muscle wasting phenotype. HDAC6 can interact with MAFbx and is required for MAFbx-mediated degradation of MyoD. According to our results, forced expression of a MyoD mutant resistant to HDAC6 and MAFbx dependent degradation prevents muscle wasting induced by denervation. Furthermore, some preliminary data show an involvement of HDAC6 in the degradation of eIF3-f and in the autophagy process in muscle tissue, revealing a double role of HDAC6 in skeletal muscle.These evidences suggest that HDAC6 potentially represents a valuable target for curative treatments.

Neste estudo, testamos dois novos moduladores seletivos do receptor de glicocorticóide, nomeados L5 e L7, em comparação com o dexametasona, sobre aspectos estruturais, funcionais e moleculares no músculo sóleo. Ratos Wistar foram tratados com doses progressivas de dexametasona, L5 e L7 em 1 ou 7 dias. A massa corporal e a ingestão alimentar apresentaram queda após o tratamento com dexametasona em todas as doses; os tratamentos com L5/L7 mostraram resposta semelhante aos controles. O peso do músculo foi diminuído pelo dexametasona, efeito não observado nos tratamentos com L5/L7. Apenas o tratamento com dexametasona causou uma diminuição na área de secção transversa dos tipos de fibra muscular analisada. A força tetânica do sóleo foi diminuída pela dexametasona, nos tratamentos com L5/L7 este parâmetro também não foi afetado. A expressão gênica de MAFbx/Atrogin-1 e MuRF-1 foi elevada pela dexametasona; por outro lado, L5/L7 não elevaram a expressão destes genes. Concluímos que o L5/L7, em contraste com o dexametasona, preveniu o músculo esquelético da atrofia. / In this study, we have tested two new selective modulators named L5 and L7 along with dexamethasone in skeletal muscle structural, functional and molecular aspects. Male Wistar rats were treated with progressive doses of dexamethasone, L5 and L7 for 1 and 7 days. While body weight and food intake were decreased by the dexamethasone treatment in all doses, L5/L7 treatments induced gain in body weight similarly to controls. Muscle weight was decreased by dexamethasone, while L5/L7 were ineffective. Only the dexamethasone treatment caused a decrease in the analyzed cross sectional area of the skeletal muscle fiber types. Soleus tetanic force was decreased by the dexamethasone treatment, while L5/L7 treatments did not alter this parameter. MAFbx/Atrogin-1 and MuRF-1 gene expressions were elevated by dexamethasone; on the other hand, L5/L7 did not modulate any expression of those genes. We conclude that L5/L7, in contrast to dexamethasone, spare skeletal muscle from structural and functional loss, and molecular changes, reinforcing their role as a therapeutic device.

Denervation leads to skeletal muscle atrophy, which is a decrease in muscle mass and force; the latter exceeding expectation from mass loss. In some cases, nerve regeneration following an injury takes several months. During this time, muscle mass and force loss become severe as fibers are replaced by connective and fat tissue, which can further prolongs normal muscle function recovery once reinnervation occurs. The objectives of this study were 1) document the angiotensin 1-7 (Ang 1-7) hypertrophic effect in innervated mouse skeletal muscle; 2) test the hypothesis that Ang 1-7 prevents muscle atrophy and maintain force following short 2 and 4 week denervation; 3) as well as following long 16 week denervation. Innervated and denervated mice were treated with Ang 1-7 or diminazene aceturate (DIZE), an ACE2 activator, to increase plasma Ang 1-7 level. In normal innervated extensor digitorum longus (EDL) and soleus muscle, Ang 1-7 increased muscle weight, cross sectional area (CSA) and tetanic force, which represents the muscle maximum force. During the short denervation period (2-4 weeks), Ang 1-7 did not prevent muscle mass and CSA loss, but fully abolished the loss of normalized tetanic force to CSA while accentuating twitch force. Normalized tetanic force was maintained as Ang 1-7 partially reduced the extent of membrane depolarization which normally observed with denervation, and it fully prevented the loss of membrane excitability. The protective effect of Ang 1-7 on maximum tetanic force was also observed after 16 weeks of denervation, but only in EDL not in soleus. About 35-40% of denervated EDL and soleus muscle fibers became reinnervated over the 16 week period and Ang 1-7 enhanced the recovery of muscle mass and tetanic force in both EDL and soleus. All Ang 1-7 effects on twitch and tetanic force were completely blocked by A779, a Mas receptor (MasR) antagonist, and were not observed in MasR deficient (MasR / ) muscles. Ang 1-7 did not affect how denervation modulates changes in the protein content MuRF-1 atrogin-1, two atrophic proteins, total and phosphorylated Akt, S6K and 4EPB, three hypertrophic proteins. So, the Ang 1-7 effect involves an activation of its MasR, but it is not clear which intracellular pathway it then affects. This is the first study providing evidence that Ang 1-7 maintains normal muscle function in terms of tetanic force and membrane excitability during 2, 4 and 16 week denervation periods.

Skeletal muscle is a highly adaptable tissue that comprises approximately 40% of total body weight while accounting for up to 90% of whole-body oxygen consumption and energy expenditure during exercise. The loss of skeletal muscle protein and subsequent decrease in muscle mass (atrophy) that accompanies disuse results primarily from a decrease in intracellular protein synthesis combined with an increase in proteolytic activity. Interestingly, these processes of skeletal muscle atrophy are amplified by changes in mitochondrial capacity, with evidence suggesting that the maintenance of mitochondria during periods of disuse protects skeletal muscle against atrophy. Remarkably, rodents with denervated muscle are protected against muscle atrophy following whole-body heat stress. The mechanism of protection appears to be tied to the observed increases in heat shock protein (HSP) and PGC-1α, which accompany the heat stress. Without any published observations as to whether such heat-induced protection against muscle atrophy would translate to human muscle, the aim of this project was to determine the extent to which deep tissue heating (via pulsed shortwave diathermy) might provide protection against skeletal muscle atrophy.

No description available.

The objective of this study was to examine the influence of age on food intake, tissue and organ mass and NF-ĸB and SIRT6 levels in various tissues. The transcription factor, Nuclear Factor Kappa-B (NF-ĸB), is associated with both catabolic and anabolic pathways of muscle metabolism and may be involved in age-related muscle loss. SIRT6 is a member of the sirtuin family of proteins that function as protein lysine deacetylases and are associated with longevity in a number of organisms. Male Sprague-Dawley rats, aged 6 months (Adult) and 21 months (Old) were fed a commercially available diet for 10-17 days. Old rats consumed less food per body weight (BW) each day than Adult rats (1.45% g diet/g BW vs. 2.4% g diet/g BW). However, when intake data were expressed as g/diet per day there was no significant difference between groups. For skeletal muscle tissue, the average mass of gastrocnemius and soleus (g muscle/g BW) was significantly lower in Old rats. Levels of NF-ĸB (p65/RelA) and SIRT6 were measured by Western blot analysis in gastrocnemius, tibialis anterior, quadriceps, soleus, lung, heart, kidney and liver. NF-ĸB levels were higher in gastrocnemius of Old rats compared to Adult rats. No significant age-specific differences in SIRT6 protein levels were noted in the tissues examined. Interestingly, when examined independent of age, levels of SIRT6 were significantly different between certain tissues. Data from this study suggest that age affects muscle loss and NF-ĸB in a tissue-specific manner. Furthermore, these findings indicate tissue-specific but not age-specific differences in SIRT6 protein levels.

Muscle disorders and induced muscle atrophy impose critical risks to the well-being of an individual, limiting normal activities of daily living. Several resistance training methods have effectively reversed the progression of muscle atrophy. Weightlifting and hydrotherapy are the two widely practiced schemes for resistance training; however, there is the potential risk of excessive loads exerted on the muscles during weightlifting, and limited accessibility and cost are barriers to hydrotherapy. An alternative is using a resistance band. Some limitations include engaging multiple muscles/joints while only unidirectional resistance is feasible. To address these limitations, a VAriable Resistance Suit (VARS) was designed to provide speed-dependent, bi-directional, and variable resistance at a single joint. As a proof of concept, an elbow module of VARS was developed and validated experimentally through a pilot study [15]. This thesis aims to investigate the feasibility of modulating speed-dependent and adjustable resistance at the targeted joints using a VAriable Resistance Suit and investigate the efficacy of the Variable Resistance Suit to induce muscle hypertrophy. The pilot study shows the changes in flexor and extensor muscle activations in response to eight different levels of resistance modulated by VARS. Furthermore, the evaluation of training using VARS on muscle hypertrophy with a focus on the increase in muscle size and strength has been conducted through a prolonged study involving 12 participants. Some sections of this thesis are reused from our published conference paper which I co-author [15].